Related Experiment Video
Updated: Jul 19, 2025

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
Published on: September 30, 2021
Cost of Care for Patients With Cirrhosis
Fasiha Kanwal1,2,3,4, Richard Nelson5, Yan Liu1,2,3,4
1Section of Gastroenterology and Hepatology, Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.
Insights
Patients with cirrhosis incur significantly higher healthcare costs, with complications driving the majority of expenses. Preventing these complications offers the greatest potential for cost savings in cirrhosis care.
Area of Science:
- Health Economics
- Gastroenterology
- Clinical Research
Background:
- Longitudinal data on cirrhosis treatment costs are limited, hindering value-based healthcare initiatives.
- Understanding the economic burden of cirrhosis is crucial for resource allocation and cost-saving strategies.
Purpose of the Study:
- To estimate the incremental annual healthcare costs associated with cirrhosis.
- To analyze cost variations based on cirrhosis severity, complications, and comorbidities.
Main Methods:
- Retrospective cohort study of Veterans Affairs patients from 2011-2019.
- Comparison of 39,361 patients with cirrhosis against 138,964 matched controls.
- Cost analysis stratified by cirrhosis severity, complications (ascites, encephalopathy, etc.), and Deyo index.
Main Results:
- Incremental annual costs for cirrhosis patients were $35,029 in year 1, decreasing to $14,216-$17,629 in subsequent years.
- Cirrhosis complications significantly increased costs; hepatic encephalopathy ($50,080) and ascites ($50,364) were most expensive in year 1.
- Patients with acute kidney injury ($64,413) or multimorbidity ($66,653) incurred the highest first-year costs.
Conclusions:
- Cirrhosis substantially elevates healthcare expenditures compared to controls, with multimorbidity further increasing costs.
- Cirrhosis complications are the primary drivers of excess costs, highlighting complication prevention as a key target for cost reduction.
Introduction:
There are limited longitudinal data on the cost of treating patients with cirrhosis, which hampers value-based improvement initiatives.
Methods:
We conducted a retrospective cohort study of patients with cirrhosis seen in the Veterans Affairs health care system from 2011 to 2015. Patients were followed up through 2019. We identified a sex-matched and age-matched control cohort without cirrhosis. We estimated incremental annual health care costs attributable to cirrhosis for 4 years overall and in subgroups based on severity (compensated, decompensated), cirrhosis complications (ascites, encephalopathy, varices, hepatocellular cancer, acute kidney injury), and comorbidity (Deyo index).
Results:
We compared 39,361 patients with cirrhosis with 138,964 controls. The incremental adjusted costs for caring of patients with cirrhosis were $35,029 (95% confidence interval $32,473-$37,585) during the first year and ranged from $14,216 to $17,629 in the subsequent 3 years. Cirrhosis complications accounted for most of these costs. Costs of managing patients with hepatic encephalopathy (year 1 cost, $50,080) or ascites ($50,364) were higher than the costs of managing patients with varices ($20,488) or hepatocellular cancer ($37,639) in the first year. Patients with acute kidney injury or those who had multimorbidity were the most costly at $64,413 and $66,653 in the first year, respectively.
Discussion:
Patients with cirrhosis had substantially higher health care costs than matched controls and multimorbid patients had even higher costs. Cirrhosis complications accounted for most of the excess cost, so preventing complications has the largest potential for cost saving and could serve as targets for improvement.
More Related Videos
Related Concept Videos
Esophageal Varices-II: Clinical Features and Management
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
Chronic Pancreatitis II: Collaborative Care
Assessment:
Restorative Care
Diseases of the Liver and Gallbladder
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
Continuing Care
Chronic Kidney Disease III: Interprofessional Care

